Sequent Scientific Quarterly Results for Trading Insights
In Sept 2025, Sequent Scientific (SEQUENT) reported revenue ₹426 Cr and net profit ₹20 Cr — revenue +14.2% YoY. Analyse SEQUENT shareholder distribution to track promoter, FII and institutional holdings.
SEQUENT Quarterly Results — Revenue, Profit & EPS Highlights
Sequent Scientific latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View SEQUENT 52-week high low for the annual high/low range and current price position.
- Revenue of ₹426 Cr in Sept 2025 (+5.7% vs Mar 2025, +14.2% vs Sept 2024)
- Net Profit of ₹20 Cr in Sept 2025 (+100.0% vs Mar 2025, +233.3% vs Sept 2024)
- EBITDA of ₹56 Cr in Sept 2025 (+16.7% vs Mar 2025)
- Operating Margin of 13.0% in Sept 2025 (+2.0pp vs Mar 2025)
- Earnings Per Share of ₹0.59 in Sept 2025 (+59.5% vs Mar 2025)
Sequent Scientific Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SEQUENT quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 426 | 403 | 445 | 373 | 365 | 5.7% | 14.2% |
| Net Profit (₹ Cr) | 20 | 10 | 18 | 6 | 1 | - | - |
| EBITDA (₹ Cr) | 56 | 48 | 55 | 39 | 32 | - | - |
| EPS (₹) | 0.59 | 0.37 | 0.57 | 0.11 | -0.04 | - | - |
| Operating Margin (%) | 13.0% | 11.0% | 12.0% | 9.0% | 8.0% | - | - |
SEQUENT Share Price Trend — 1-Year Movement Across Quarterly Results
Sequent Scientific 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit SEQUENT screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SEQUENT vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Sequent Scientific latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores